85 results about "Ejection fraction" patented technology

The invention discloses a monitoring method and system and a related device, which are applied to first electronic equipment, the first electronic equipment is provided with a first circuit, and the first circuit comprises a first electrode, a second electrode, a third electrode, a fourth electrode, an excitation current generation unit and a voltage measurement unit; receiving and responding to a first instruction, and determining that the first electrode and the second electrode are in good contact with skin through a first circuit; first information is determined through the first circuit, the first electrode makes contact with a first position of the user skin, the second electrode makes contact with a second position of the user skin, and the first position and the second position are located at the two ends of the thoracic cavity tissue respectively; and outputting first information, wherein the first information comprises one or more of the following items: cardiac output, stroke output, heart rate, ejection fraction and cardiac function judgment result. Therefore, the heart function condition of the user can be monitored in real time, and the user can conveniently monitor anytime and anywhere.

The invention relates to the field of biomedicine, in particular to application of PXDC1 in preparation of a product for treating myocardial hypertrophy. The invention discloses the effectiveness of inhibiting PXDC1 expression in treating cardiac hypertrophy and controlling the occurrence and development process of the cardiac hypertrophy for the first time. The invention provides a novel drug target and strategy for treating myocardial hypertrophy, and the novel drug target and strategy can reduce the expression of a myocardial hypertrophy biomarker, reduce the size of myocardial cells, improve the ejection fraction and short axis shortening rate of the heart, reduce the weight ratio of the heart and relieve the degree of myocardial fibrosis. Besides, the invention clarifies the action mechanism of PXDC1 in myocardial hypertrophy, deepens the understanding of the pathogenesis of the disease, and lays an important foundation for further exploration of myocardial hypertrophy-related cytobiology and molecular biology processes.

The invention relates to the field of biological detection, in particular to application of IGSF1 protein as a cardiac function recovery marker. The invention provides application of protein as a marker in preparation of a product for detecting and / or diagnosing heart failure with improved ejection fraction. The protein comprises one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4, and is characterized in that the protein comprises one or more of the IGSF1, the LIMS1, the MPP1, the PTX3, the SLC2A3, the FERMT3, the ARPC1B, the IGHG1 The invention provides a novel serum marker, the expression level of the novel serum marker can predict heart failure patients with reduced ejection fraction and heart function recovery potential with high precision, and the change of the novel serum marker is earlier than the change of ejection fraction. According to the invention, a non-invasive standardized detection process based on a serum sample is established, all levels of medical institutions are adapted, and early and non-invasive prediction of the heart function recovery potential of the heart failure patient is realized.

The invention relates to the technical field of medical biology, and discloses an application of a biomarker in the diagnosis of ejection fraction retention type heart failure, and the biomarker is kynuric acid. The biomarker is applied to preparation of a product for diagnosing or predicting ejection fraction retention heart failure. According to the method, the ejection fraction retention heart failure can be diagnosed by quantitatively detecting the kynuric acid in the plasma.

The invention relates to the technical field of medical detection, in particular to application of a TTR tetramer in preparation of a product for diagnosing ejection fraction retention type heart failure. Experiments prove that in heart failure patients, TTR tetramers in HFpEF patients are obviously higher than those in non-HFpEF patients, and it is prompted that the TTR tetramers are related to HFpEF. According to the present invention, the diagnosis model and the kit using the TTR tetramer as the biomarker have good sensitivity and good specificity, can achieve the diagnosis or the auxiliary diagnosis, the treatment guidance and the prognosis of the HFpEF, and can improve the identification of different heart failure types such as the HFpEF and the non-HFpEF.

A method comprising is described herein comprising receiving first magnetic resonance imaging (MRI) data of a first plurality of subjects, wherein the first MRI image data comprises a first plurality of two-dimensional (2D) images, pre-processing the first MRI data for analysis, converting each two-dimensional image of the first plurality of 2D images into first tokens as input for a transformer encoder, wherein the transformer encoder comprises a time series classification transformer, training the transformer encoder using the first input tokens, receiving second MRI data of a subject, wherein the second MRI data comprises a second plurality of 2D images, converting each image of the second plurality of 2D images into second tokens as input to the trained transformer encoder, and applying the trained transformer encoder to the second tokens to predict a state of disease in a subject.

The invention relates to the technical field of medical care, in particular to a cardiovascular disease risk dynamic early warning system based on multi-source data fusion, and the system comprises the steps: obtaining ejection fraction, coronary artery stenosis percentage and calcification integral data of cardiovascular examination of a monitored object, and heart rate data and pulse pressure difference data of periodic signs; determining a physical examination abnormal coefficient according to the difference between the ejection fraction and the standard value and the difference between the calcification integral data and the standard value and the coronary artery stenosis percentage; according to the height and slope difference of the ST wave band and the PR wave band, the heart rate analysis abnormal index is determined by combining the time interval of the adjacent electric activity wave bands; according to the time sequence change correlation of the heart rate data and the pulse pressure difference data, a physical sign abnormal coefficient is determined; determining a dynamic risk score in combination with the physical examination abnormal coefficient and the physical sign abnormal coefficient; and carrying out risk early warning based on the dynamic risk score. According to the invention, fusion analysis of multi-source and multi-dimensional data can be realized, and the dynamic early warning precision of cardiovascular risks is improved.

A cardiovascular analysis application receives patient echocardiograms as video segments and performs an analysis for cardiovascular health based on factors related to an ejection fraction and hypertrophic cardiomyopathy based on the images in the video segment and spatiotemporal features extracted from the images through several heartbeat cycles on the video segments. The models are trained on a corpus of previous echocardiograms including labels indicative of the ejection fraction and physiological markers associated with HCM, such as the cardiac wall thickness and clarity. Based on a correspondence with the model, a result is rendered indicative of whether the patient video segment has an insufficient ejection fraction and whether a presence of HCM is exhibited.

Described herein are systems and methods for characterizing a subject's ejection fraction (EF) status, heart failure status, and / or sleep apnea status. In particular, described herein are systems and methods for characterizing a subject's EF status, heart failure status, and / or sleep apnea status through use of a wearable electrocardiogram (ECG) device having LII and LIII leads, and software configured to incorporate data from the ECG device and assess the subject's EF status, heart failure status, and / or sleep apnea status.

The invention discloses the field of medicine, and particularly relates to a biomarker for diagnosis and prognosis evaluation of heart failure and application of the biomarker, AQP1 and Scr biomarkers are screened out, and by measuring AQP1 and Scr levels in serum, heart failure patients can be effectively recognized, typing diagnosis of HFrEF, HFmrEF and HFpEF can be distinguished, the severity of illness states of the patients can be evaluated, and the risk of re-admission of the patients can be predicted. The synergistic effect of AQP1 and Scr can complement the deficiency of a single index, improve the diagnosis efficiency, especially have high specificity on ejection fraction reduced heart failure (HFrEF), and can formulate a more accurate treatment scheme for patients.

An example system for determining a reduction in ejection fraction includes two or more electrodes forming a single lead configured to capture an electrocardiogram (EGM) signal of a patient; a circuit configured to: convert the EGM signal to a time-frequency domain using a continuous wavelet transform; and applying the converted EGM signal to a convolutional neural network to determine one or more of: an amount of ejection fractions or a classification of ejection fractions.

An example system for determining reduced ejection fraction includes two or more electrodes forming a single lead configured to capture a cardiac electrogram (EGM) signal of a patient, circuitry configured to: convert the EGM signal to a time -frequency domain using a continuous wavelet transform; and apply the converted EGM signal to a convolutional neural network to determine one or more of an amount of ejection fraction or a classification of ejection fraction.

The invention relates to the technical field of medical animal model construction, in particular to a construction method and application of a cardiomyopathy animal model induced by a circulating system. According to the invention, the Abeta25-35 is injected into the adventitia, so that the animal model of the cardiomyopathy induced by the Abeta25-35 through the tissue fluid circulatory system of the adventitia is constructed in the SD rat for the first time. In the model, A beta 25-35 is subjected to myocardial perfusion through lower limb vascular adventitia to induce myocardial diffuse fibrosis and ejection fraction reduction of SD rats, which are in accordance with epidemiological research data. The model can be used for subsequently researching the pathogenic mechanism of A beta25-35 induced cardiomyopathy and a novel treatment method taking vascular adventitia tissue fluid transmission as a way, and also provides a brand new view angle for researching the pathogenic mechanism of AD or cerebrovascular diseases and a diagnosis and treatment method.

The present invention relates to the field of pharmaceutical technology, and specifically to the application of a macrolide derivative in the preparation of a drug for treating heart failure. The present invention provides a new use of a macrolide derivative. Experimental results show that this macrolide derivative significantly improves the cardiac function of heart failure mice, increases the ejection fraction (EF%), fractional shortening (FS%), and cardiac output per minute (CO), without changing the heart rate (HR), is equivalent to the positive drug digoxin, and is superior to enalapril; at the same time, it has the effects of reducing the heart weight ratio, improving myocardial hypertrophy and fibrosis, and has good clinical prospects and social benefits.

The invention discloses an intelligent echocardiography heart function accurate evaluation system and method, and the system collects a heart image through an ultrasonic instrument, determines the ventricular diastole and contraction period through a data processing module, employs an image segmentation technology to extract the heart image, employs a cubic interpolation method to standardize the size of the image, and achieves the accurate evaluation of the heart function. The system constructs a graph model, spatial and temporal features of a heart image are extracted through a spatial and temporal feature extraction module by using a 3D convolutional neural network of a C3D structure fusing spatial and temporal features, a graph convolutional network module performs feature aggregation and message passing on the image through a multi-layer edge condition convolution ECC layer to obtain feature descriptors fusing all cavity information, and the feature descriptors are used for analyzing the cavity information. The ejection fraction prediction module inputs the characteristics into a full-connection layer for ejection fraction prediction; the invention innovatively provides an intelligent analysis framework based on a cardiac ultrasound dynamic image video, and aims to realize comprehensive and accurate evaluation of cardiac functions.

An apparatus for producing information indicative of a heart failure with reduced ejection fraction HFrEF comprises a signal interface 101 for receiving a signal indicative of cardiac angular rotation

This invention belongs to the field of traditional Chinese medicine, specifically disclosing a traditional Chinese medicine composition patch for the adjunctive treatment of chronic heart failure and its preparation method. The traditional Chinese medicine composition patch is made from processed aconite root, pokeweed, lepidium seed, and chuanxiong rhizome. The drugs of this invention are prepared into a traditional Chinese medicine composition patch by mixing the ingredients with an adhesive in a specific ratio. The patch exhibits high bioavailability, clearly defined components, and good therapeutic effects. Furthermore, by controlling the specific types and proportions of the active ingredients, the synergistic effect between the components is improved, enhancing the therapeutic effect on chronic heart failure with reduced ejection fraction. The rational combination of the drug components, when applied to the Shenque acupoint, can significantly improve the clinical symptoms and quality of life of patients with chronic heart failure and reduced ejection fraction.

The present invention provides an oral pharmaceutical composition comprising iron succinate for use in treating iron deficiency in a subject diagnosed with heart failure (HF) with reduced ejection fraction (HFrEF), and a method for treatment is also provided.

The present invention relates to soluble guanylate cyclase (sGC) activators, preferably (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid (luncacyguat) and / or substituted pyrazolopiperidinecarboxylic acids, preferably 1-[1-{4-chloro-4’-[4-(2-methylpropyl)piperazin-1-yl][1,1’-biphenyl]-2-yl}piperidin-3-yl]-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-{3(R)-1-{4-chloro-4’-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-{3(R)-1-[4-chloro-4’-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride, 1-{3(R)-1-[4-chloro-4’-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride hemihydrate or 1-[1-{4-chloro-4’-[4-(2-methylpropyl)piperazin-1-yl][1,1’-biphenyl]-2-yl}piperidin-3-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride (enantiomer 1), for the treatment and / or prevention of heart failure with preserved ejection fraction (HFpEF) in women, and to their use for the preparation of a medicament for use in the treatment and / or prevention of heart failure with preserved ejection fraction (HFpEF) in women.

The invention discloses a heart failure biomarker and application thereof, relates to the technical field of biology, solves the technical problem that BNP is insufficient in early signal recognition of HFpEF, and is characterized by providing a biomarker LECT2 protein or LECT2 coding gene for diagnosis or auxiliary diagnosis of heart failure. The invention provides application of a product for quantitatively detecting LECT2 protein in preparation of a tool for diagnosing heart failure, the heart failure is ejection fraction retention type heart failure, a pharmaceutical composition for treating HFpEF is provided, the pharmaceutical composition comprises an LECT2 inhibitor, and the inhibitor is selected from one or more of shRNA of a targeted LECT2 gene, an antibody of the targeted LECT2 protein and an antagonist of a targeted LECT2 receptor; the effects of being beneficial to early recognition of high-risk patients and remarkably improving the accuracy of HFpEF diagnosis and the early detection capability are achieved.

The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.

The invention relates to a viral vector carrying a Prrg3 gene expression cassette and application thereof in treating diseases. Specifically, the invention relates to a Prrg3 gene expression cassette, a virus vector carrying the Prrg3 gene expression cassette and application of the virus vector in treatment of heart failure, cardiac hypertrophy, hypertension, overweight, obesity, diabetes, fatty liver, hyperlipidemia and other diseases, and the virus vector is especially suitable for ejection fraction retention heart failure patients with one or more diseases. The application provides a new thought and strategy for clinical treatment of ejection fraction retention heart failure and complications thereof, and has a wide application prospect.

Provided is use of an HPCAL1 protein in enhancing cardiac function. The HPCAL1 protein can specifically bind to a recombinant β3-adrenergic receptor, and can be used as a β3-adrenergic receptor antagonist protein. It is found in animal experiments that by intravenously injecting recombinant mouse HPCAL1 with a certain concentration into an ischemia-reperfusion mouse model, the cardiac function of the mice can be effectively improved, and the ejection fraction of the mice is enhanced, indicating that the HPCAL1 protein can be used for enhancing the cardiac function and has potential medicinal value for treating cardiovascular diseases with cardiac function decline. Moreover, the HPCAL1 protein is a class of biomacromolecules with low toxicity, which solves the problem of high hepatic and renal toxicity of small molecule chemical drugs. Therefore, the HPCAL1 protein has relatively high application value.

This invention discloses a heart failure readmission risk assessment system based on cardiac imaging feature analysis, belonging to the field of cardiac imaging analysis technology. By analyzing speckle texture features in ultrasound images and combining them with respiratory phase and image quality information, a dynamic and regular quantitative index is generated, thereby achieving accurate risk assessment. It can identify potentially high-risk patients in advance, even those with normal or mildly abnormal ejection fractions, and effectively addresses the impact of respiratory phase changes and image quality interference on assessment results. By weighted fusion of image quality and physiological state information, the stability and accuracy of the assessment results are improved, making it particularly suitable for primary healthcare institutions. This invention provides a more objective and accurate risk assessment, offering a scientific basis for doctors to develop personalized treatment plans, thereby significantly improving the early identification and treatment outcomes of heart failure patients.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for treating heart failure, its preparation method, and its use. The raw materials of the traditional Chinese medicine composition of the present invention include the following ingredients, by weight: 40-100 parts of astragalus, 8-20 parts of ginseng, 20-30 parts of salvia miltiorrhiza, and 20-35 parts of corn silk. The traditional Chinese medicine composition for treating heart failure provided by the present invention can invigorate qi, promote blood circulation, and promote diuresis, and also has significant therapeutic effects on heart failure with reduced ejection fraction.

This invention in one aspect discloses a smartport system that can continuously monitor cardiovascular function during chemotherapy sessions through ECG and dynamic ejection fraction measurements via ultrasound probes. Ultrasound probes monitor the patency of the catheter shaft through Doppler measurements of the flow. Monitoring heart function and patency of the catheter shaft are unmet needs for chemotherapy patients who receive drugs via portacath systems. This monitoring allows immediate real-time assessment of the cardiotoxicity of cytotoxic chemotherapeutic therapies.

Uses of a complex of an angiotensin II receptor antagonist metabolite and a NEP inhibitor in treating heart failure, specifically related are uses of complex in preparing a medicament for use in heart failure with reduced ejection fraction (HFrEF).

Use of an ester group-containing aromatic propanamide compound and its metabolite in the preparation of a drug for treating heart failure, wherein the ester group-containing aromatic propanamide compound is C<subgt;25< / subgt;H<subgt;17< / subgt;F<subgt;3< / subgt>N<subgt;4< / subgt>O<subgt;4< / subgt>. The ester group-containing aromatic propanamide compound can improve the reduction of ejection fraction, fractional shortening and cardiac output in rats with chronic heart failure, and increase the LVSP of heart failure rats.

The invention discloses an ultrasonic processing method for ejection fraction evaluation, and relates to the field of ultrasonic three-dimensional imaging. The method comprises the steps that an initial heart ultrasonic image set is acquired; classifying and screening all the cardiac ultrasound images to obtain cardiac feature information; performing three-dimensional modeling on the heart to obtain an ultrasonic three-dimensional image; performing time sequence modeling on the ultrasonic three-dimensional image to obtain a dynamic ultrasonic three-dimensional image; when it is judged that the dynamic ultrasonic three-dimensional image does not meet the forming condition, a feedback adjustment step is triggered and executed, and an updated dynamic ultrasonic three-dimensional image is obtained; when it is judged that the updated dynamic ultrasonic three-dimensional image does not meet the forming condition, the feedback adjustment step is triggered and executed again; when it is judged that the updated image meets the forming condition, the ejection fraction corresponding to the heart is obtained. Therefore, the dynamic ultrasonic three-dimensional image can be circularly updated through a feedback adjustment mechanism, so that the dynamic three-dimensional imaging precision is improved, and meanwhile, the EF measurement precision is also improved.

The present invention discloses the role of Amuc_1100 in the preparation of drugs that alleviate doxorubicin cardiotoxicity. In vivo experimental results show that Amuc_1100 can effectively alleviate the toxic effects of the chemotherapy drug doxorubicin on the heart. By improving the homeostasis of the body and cardiac immune cells, reducing cell apoptosis in myocardial tissue, alleviating elevated myocardial enzymes, and enhancing left ventricular diastolic capacity and cardiac ejection fraction, it reduces the toxic side effects of the chemotherapy drug doxorubicin. It also improves the intestinal barrier function damage caused by doxorubicin chemotherapy. The present invention overcomes the current limitations on the clinical use of Dox and the drawbacks of existing chemotherapy cardioprotective drugs, while also solving the problem of preventing and treating the cardiotoxicity and intestinal side effects induced by Dox chemotherapy.